JPMorgan analyst Anupam Rama raised his price target for Neurocrine Bioscience (NBIX) to $127 after conducting a survey of 25 U.S.-based physicians to better understand launch trends in the tardive dyskinesia space. The launch of Neurocrine's Ingrezza has exceeded Street expectations to date, Rama tells investors in a research note. Further, the survey indicated Ingrezza's clinical profile is preferred over Teva's (TEVA) Austedo and that the TD market is undergoing branded market expansion, the analyst adds. Doctors also expect Ingrezza to have "dominating market share" within two years, Rama notes. He keeps an Overweight rating on Neurocrine.